GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Asset Turnover

Azenta (Azenta) Asset Turnover : 0.06 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Azenta Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Azenta's Revenue for the three months ended in Mar. 2024 was $159.1 Mil. Azenta's Total Assets for the quarter that ended in Mar. 2024 was $2,693.9 Mil. Therefore, Azenta's Asset Turnover for the quarter that ended in Mar. 2024 was 0.06.

Asset Turnover is linked to ROE % through Du Pont Formula. Azenta's annualized ROE % for the quarter that ended in Mar. 2024 was -23.47%. It is also linked to ROA % through Du Pont Formula. Azenta's annualized ROA % for the quarter that ended in Mar. 2024 was -20.32%.


Azenta Asset Turnover Historical Data

The historical data trend for Azenta's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Asset Turnover Chart

Azenta Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.25 0.30 0.20 0.20

Azenta Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.05 0.06

Competitive Comparison of Azenta's Asset Turnover

For the Medical Instruments & Supplies subindustry, Azenta's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azenta's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Azenta's Asset Turnover falls into.



Azenta Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Azenta's Asset Turnover for the fiscal year that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=665.072/( (3716.122+2885.72)/ 2 )
=665.072/3300.921
=0.20

Azenta's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=159.134/( (2824.314+2563.497)/ 2 )
=159.134/2693.9055
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Azenta  (NAS:AZTA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Azenta's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-547.52/2333.2675
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-547.52 / 636.536)*(636.536 / 2693.9055)*(2693.9055/ 2333.2675)
=Net Margin %*Asset Turnover*Equity Multiplier
=-86.02 %*0.2363*1.1546
=ROA %*Equity Multiplier
=-20.32 %*1.1546
=-23.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Azenta's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-547.52/2693.9055
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-547.52 / 636.536)*(636.536 / 2693.9055)
=Net Margin %*Asset Turnover
=-86.02 %*0.2363
=-20.32 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Azenta Asset Turnover Related Terms

Thank you for viewing the detailed overview of Azenta's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Azenta (Azenta) Business Description

Traded in Other Exchanges
Address
200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Executives
Herman Cueto officer: EVP, Chief Financial Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes officer: VP, Chief Accounting Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray officer: Chief Strategy & New Business C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin director
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne officer: SVP and GM, Life Sciences Proj 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou officer: SVP and General Manager, Genom 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus officer: EVP & Chief Operating Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson officer: EVP & Chief Financial Officer C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley officer: Chief Human Resources Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram officer: VP, Finance & Corp. Controller 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De officer: Chief Commercial Officer, LS 15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka officer: Sr. VP, General Manager 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha officer: SVP, GM BLS-Products 15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824